DnB Asset Management AS Buys 279 Shares of The Cooper Companies, Inc. (NASDAQ:COO)

DnB Asset Management AS boosted its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 0.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,332 shares of the medical device company’s stock after buying an additional 279 shares during the quarter. DnB Asset Management AS’s holdings in Cooper Companies were worth $3,156,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in shares of Cooper Companies during the 4th quarter worth $691,000. Highland Capital Management LLC bought a new position in Cooper Companies during the 4th quarter worth about $4,004,000. Caprock Group LLC purchased a new position in Cooper Companies during the 4th quarter valued at about $282,000. Franklin Resources Inc. raised its holdings in shares of Cooper Companies by 194.0% in the 3rd quarter. Franklin Resources Inc. now owns 48,892 shares of the medical device company’s stock valued at $5,265,000 after purchasing an additional 32,260 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its position in shares of Cooper Companies by 6.6% in the 3rd quarter. Principal Financial Group Inc. now owns 238,305 shares of the medical device company’s stock worth $26,295,000 after purchasing an additional 14,687 shares during the period. 24.39% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on COO shares. Needham & Company LLC reissued a “hold” rating on shares of Cooper Companies in a research note on Friday, March 7th. StockNews.com cut Cooper Companies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Robert W. Baird cut their target price on Cooper Companies from $117.00 to $107.00 and set an “outperform” rating on the stock in a research note on Friday, March 7th. JPMorgan Chase & Co. decreased their price target on shares of Cooper Companies from $120.00 to $110.00 and set an “overweight” rating for the company in a research report on Friday, March 7th. Finally, Wells Fargo & Company lifted their price objective on shares of Cooper Companies from $115.00 to $118.00 and gave the stock an “overweight” rating in a research report on Friday, December 6th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $110.25.

Cooper Companies Stock Up 0.7 %

Shares of COO stock opened at $84.35 on Tuesday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91. The Cooper Companies, Inc. has a fifty-two week low of $77.05 and a fifty-two week high of $112.38. The firm has a market capitalization of $16.87 billion, a PE ratio of 43.26, a P/E/G ratio of 2.25 and a beta of 1.02. The stock’s 50-day simple moving average is $89.15 and its 200-day simple moving average is $97.03.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.92. The company had revenue of $964.70 million during the quarter, compared to analyst estimates of $981.25 million. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. Equities analysts expect that The Cooper Companies, Inc. will post 3.98 earnings per share for the current year.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.